

DERMA SCIENCES, INC.  
Form 8-K  
August 07, 2015

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 3, 2015

**Derma Sciences, Inc.**

(Exact name of registrant as specified in its charter)

Delaware                      1-31070      23-2328753  
(State or other jurisdiction (Commission (IRS employer  
of incorporation)              File Number) identification number)

214 Carnegie Center, Suite 300

Princeton, NJ 08540

(609) 514-4744

(Address including zip code and telephone

number, of principal executive offices)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

Edgar Filing: DERMA SCIENCES, INC. - Form 8-K

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**

On Monday, August 3, 2015, John Caminis, M.D., former Chief Medical Officer of Derma Sciences, Inc. (the “Company”), resigned effective as of August 10, 2015 (the “Effective Date”). The resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Pursuant to the terms of Dr. Caminis’ employment agreement with the Company, such employment agreement will be terminated on the Effective Date.

**Item 8.01 Other Events**

Following Dr. Caminis’ resignation, the Company has agreed that Alan Dunton, M.D., who has been a senior medical consultant to the Company’s development program for the past three years, will act in the capacity of Chief Medical Officer by assuming the duties and obligations of such role in his current position of senior consultant.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DERMA SCIENCES, INC.

By: /s/ John E. Yetter  
John E. Yetter, CPA  
Executive Vice President, Finance and Chief Financial Officer

Date: August 7, 2015